Inventor profile of:

Lai Wang

City:

Beijing

Country:

China

Published Applications:

14

Last publication date:

2026-05-28

Top Assignees for applications by Lai Wang

The entities that hold a legal rights for patent applications filed by inventor Wang Lai:

Recent patent applications by Wang Lai

Lai Wang from Beijing, CN has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-05-28
US20260150047A1
Electricity

SIGNAL RECEIVING METHOD, SIGNAL SENDING METHOD, SIGNAL RECEIVING APPARATUS, AND SIGNAL SENDING APPARATUS

#2 | 2024-04-11
US20240116940A1
Chemistry; metallurgy

Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)- 2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof

#3 | 2023-11-16
US20230364096A1
Human necessities

USE OF A COMBINATION COMPRISING A BTK INHIBITOR FOR TREATING CANCERS

#4 | 2023-08-03
US20230242542A1
Chemistry; metallurgy

COMPOSITIONS COMPRISING (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE

#5 | 2023-03-23
US20230089557A1
Human necessities

METHODS OF TREATING DLBCL USING BTK INHIBITORS AND COMBINATIONS THEREOF

#6 | 2022-10-27
US20220340583A1
Chemistry; metallurgy

Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof

#7 | 2022-09-08
US20220281881A1
Chemistry; metallurgy

Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof

#8 | 2021-09-09
US20210275530A1
Human necessities

Treatment of B cell cancers using a combination comprising Btk inhibitors

#9 | 2021-07-29
US20210228553A1
Human necessities

Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer

#10 | 2021-07-08
US20210205323A1
Human necessities

MAINTENANCE THERAPY OF A PARP INHIBITOR IN TREATING GASTRIC CANCER

#11 | 2021-05-20
US20210147543A1
Chemistry; metallurgy

Immunotherapy for hepatocellular carcinoma

#12 | 2020-05-21
US20200155567A1
Human necessities

TREATMENT OF CANCERS USING A COMBINATION COMPRISING PARP INHIBITORS, TEMOZOLOMIDE AND/OR RADIATION THERAPY

#13 | 2020-03-05
US20200069666A1
Human necessities

Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer

#14 | 2020-01-30
US20200030339A1
Human necessities

Treatment cancers using a combination comprising PARP inhibitors

InventorID:

2626708 ⎘